What’s your “why”?
“Transforming Lives for Generations” is the purpose of Boehringer Ingelheim that inspires the company’s more than 53,000 employees.
Read more
January
Global Top Employer
Boehringer Ingelheim is once again a Global Top Employer! Scoring particularly high in the area of rewards and recognition as well as agile work environment, company’s values, ethics and integrity, the company received the award in 29 countries.
February
Accelerated approval of BI 1015550
Following promising study results in Phase II, the U.S. regulatory authority, the Food & Drug Administration (FDA), grants the substance BI 1015550 Breakthrough Therapy Designation (BTD) status as an oral therapy for idiopathic pulmonary fibrosis, thus clearing the way for an accelerated approval process.
March
JARDIANCE® for heart failure
JARDIANCE® (empagliflozin) is the first and only medicine to be approved in Europe for treatment of adults with chronic heart failure independent of the ejection fraction. This extends the existing indication to adults with heart failure with preserved ejection fraction, an underserved patient group for whom no approved therapies have previously existed in Europe. The European approval follows approval by the U.S. Food & Drug Administration (FDA), granted on February 24, 2022.
April
New stem cell therapy for horses
Boehringer Ingelheim launches RenuTend™, a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses. A single dose improves fiber alignment and decreases scar tissue formation. RenuTend™ will be available across the European Union.
May
Fast and effective swine vaccination with TwistPak®
Prize-winning design and patented technology: TwistPak® makes it possible to mix Ingelvac CircoFLEX® and Ingelvac MycoFLEX® vaccines in less than five seconds – easily, flexibly while decreasing the workload for swine producers and increasing the well-being of pigs.
June
Partnership with CarthroniX
Boehringer Ingelheim and CarthroniX announce a research partnership. CarthroniX is a biopharmaceutical company that focuses on the development of low-molecular therapies for degenerative and age-related diseases. The companies intend to work together to develop low-molecular therapies for oncology in dogs.
July
Aurobac: joint venture for the fight against AMR
Boehringer Ingelheim, life science company Evotec and bioMérieux, one of the world’s leading providers of in vitro diagnostics, announce the establishment of a joint venture. The joint company, Aurobac Therapeutics, will develop a new approach to combating anti-microbial resistance.
August
Boehringer Ingelheim makes fundamental progress in research and development
In the first half of 2022, Boehringer Ingelheim continued to improve the supply of medicines to patients and expanded its research pipeline in an increasingly difficult economic, political and regulatory environment. Thanks to continued strong demand for products to treat heart failure, diabetes and respiratory diseases in humans as well as products for pets, currency-adjusted net sales increased by 9.5 percent to 11.2 billion euros.
September
FDA approves therapy for GPP flare-ups in adults for the first time
The U.S. public health authority is the first regulatory authority to approve spesolimab for the treatment of generalized pustular psoriasis (GPP) in adults. The innovative, selective antibody is marketed in the USA as SPEVIGO®. It blocks activation of the interleukin-36 receptor (IL-36R), a pathway in the immune system that is verifiably involved in the development of GPP. In October the company’s marketing authorization application for spesolimab was validated by and is now under evaluation with the European Medicines Agency.
October
Making More Health Together: international hybrid convention
For the second time and under the umbrella of Making More Health (MMH), people met in Ingelheim (Germany), Nairobi (Kenya) as well as virtually, to exchange action-oriented ideas and to build partnerships with the goal of addressing the most urgent global health issues of our time. MMH is a long-term partnership between Boehringer Ingelheim and Ashoka, the world’s largest network of social entrepreneurs. It combines innovative socio-entrepreneurial solutions with business expertise to meet complex health care challenges, thereby creating more sustainable global solutions.
Social start-up Cowtribe receives investment
Cowtribe, a leading last-mile veterinary delivery company from Ghana, is the first recipient of investment and non-financial support from the Boehringer Ingelheim Social Engagement (BI SE) initiative. The program aims to close a critical financing gap for social businesses in vulnerable communities. Cowtribe is a social start-up that bridges the final, critical last mile to get animal medication and veterinary vaccines to smallholder farmers in remote areas by using innovative solutions, such as software supported demand and supply matching, as well as a partnership for drone delivery.
November
EMPA-KIDNEY trial full results disclosed
EMPA-KIDNEY is the first Phase III chronic kidney disease trial to demonstrate a statistically significant reduction in hospitalization for any cause, bringing relief for patients and reducing burden on healthcare systems. The largest and broadest dedicated SGLT2 inhibitor CKD trial to date, it is reflective of the CKD population, including adults with CKD who have been historically under-represented in previous SGLT2 inhibitor trials, addressing a critical unmet need.
